Sertraline-induced periorbital purpura: a case report.
OBJECTIVE
The incidence of mild to severe levels of spontaneous bleeding due to the usage of selective serotonin reuptake inhibitors (SSRIs) is relatively low. Although the exact mechanism is not known, it is thought that inhibition of the serotonin transporter together with a decrease in platelet serotonin could be responsible for the bleeding. Therefore, the use of SSRIs in conjunction with anti-aggregants may predispose to or exacerbate the risk of bleeding. In this case report, we describe a 44-year-old female patient with a diagnosis of anxiety disorder who spontaneously developed periorbital purpura during treatment with sertraline.


CONCLUSION
Abnormal bleeding after treatment with an SSRI should be kept in mind, and alternative non-SSRI drugs of choice in such cases would be more appropriate. More extensive and comprehensive studies focusing on hemostasis and bleeding disorders are needed for SSRIs such as sertraline.
['Kayhan|Fatih|F|', 'Eken|Zahide Eriş|ZE|', 'Uguz|Faruk|F|']
D000328:Adult D001008:Anxiety Disorders D005260:Female D006470:Hemorrhage D006801:Humans D009916:Orbital Diseases D011693:Purpura D017367:Serotonin Uptake Inhibitors D020280:Sertraline
purpura bleeding sertraline side effect